# 3D Printed Drugs Market, Size, Share, Growth, Opportunity and Forecast, 2021-2028 | DataM Intelligence

**The Global 3D Printed Drugs Market is expected to grow at a CAGR of 19.20% during the forecasting period (2021-2028).**

**Washington, Bremerton, Aug 10, 2021 (Issuewire.com) - Market Overview**

3D printed drugs are drugs manufactured by solidifying layers of materials to form a definite 3D structure. The adaptability of 3D printing is also applied for the precise and unique dosing of medicines, to present more efficient drug administration. 3D printing is expected to be an efficient method to enhance the application of several controlled drug release mechanisms, during the forecast period.

**View full report: https://www.datamintelligence.com/research-report/3d-printed-drugs-market**

**Market Dynamics**

The global 3D Printed Drugs market growth is driven by several factors such as rising healthcare disorders globally and rising demand for cheaper drugs or pills, and increasing adaptability of 3D printing in the medical industries. With rising awareness towards the advantages of 3D printed drugs, such as their instantaneous solubility. 3D printed drugs are extremely easy to swallow. As these drugs can be customized according to the requirement of every patient, assisting way better than batch-

produced drugs, the demand is expected to grow over the forecast period.

In addition, the increasing advancements in 3D printing technology and the rising investments to increase the research activities for the development of highly efficient 3D printed drugs are also expected to boost the growth of the market during the forecast period. For instance, in December 2017, Aprecia and Cycle Pharmaceuticals from Cambridge in the UK announced a partnership to develop and commercialize 3D printed tablets for orphan (rare) diseases using the ZipDose technology. In 2015, the Howard Hughes Medical Institute developed a molecular 3D printer for formulating new drugs by synthesizing blocks of small molecules from the basic chemical pattern.

New players are also entering the market with advanced technology to meet the rising demand, which creates several opportunities in the market over the forecast period. For instance, FabRX, a biotech start-up that specializes in 3D printing medicines, is providing personalized medicines and drug-loaded medical devices through their patented technologies. The company's propriety technology Print lets offer personalized dosages, polypills, chewable medicines, and fast-dissolving tablets. The company is also developing drug-loaded medical devices using SLA.

However, the adverse effect of 3d printed drugs, lack of government regulations is expected to hinder the growth of the market.  Also, there are several scandals and hacking of data that is stored online which could result in patients being increasingly reluctant regarding disclosing their medical information. In addition, mislabelling of blueprints and inputting the wrong descriptions is also a big challenge for the market as a 3D blueprint is required to be made of the patient, their dosage, and medical history to prepare a 3D printed drug.

**Market Segmentation**

**By Drug**

- Spritam
- Others

**By Technology**

- Inkjet printing
- Fused deposition modelling (FDM)
- Stereolithography (SLA)
- Others

**By End-User**

- Hospitals
- Clinics
- Research Laboratories
- Others

**Download free sample: https://www.datamintelligence.com/download-sample/3d-printed-drugs-market**

**Geographical Analysis**

North America is dominating the global 3D printed drugs market accounting for the largest market share in 2018, owing to the increasing number of chronic disorders, the presence of advanced domestic healthcare infrastructure, high investment in research and development, and rising adoption of technological advancements in 3D printing. As Aprecia Pharmaceuticals has successfully got FDA approval of the first 3D printed drug, Spritam, and currently selling in the U.S market, hence, this region is the largest contributor to the market share of 3D printed drugs.

**Competitive Landscape**

Aprecia Pharmaceuticals, FabRx Ltd. Technologies Inc., are the major players in the 3D printed drugs market and GlaxoSmithKline (GSK) is considered to be a potential player as the organization is expecting to invest considerably in the industry over the forecast period (20129-2026). Other drugmakers are expected to grab the market share in the near future on account of the swift advancements in technology.

**Related Topic's**

3D Concrete Printing Market, 3D Audio Market, 3D Printed Electronics Market, 3D Printing Metal Market, 3D Printing Plastics Market


**Media Contact**

DataM Intelligence

info@datamintelligence.com

+18774414866

India

Source : DataM Intelligence

See on IssueWire